Insight Folios Inc Takes Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Insight Folios Inc bought a new position in shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,938 shares of the medical technology company’s stock, valued at approximately $192,000.

Several other hedge funds and other institutional investors have also bought and sold shares of ATEC. First Light Asset Management LLC increased its stake in shares of Alphatec by 97.0% in the 4th quarter. First Light Asset Management LLC now owns 5,976,851 shares of the medical technology company’s stock valued at $90,310,000 after acquiring an additional 2,943,310 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of Alphatec by 1.8% during the third quarter. Vanguard Group Inc. now owns 4,615,223 shares of the medical technology company’s stock valued at $59,859,000 after purchasing an additional 80,101 shares during the period. American Century Companies Inc. boosted its position in shares of Alphatec by 24.5% during the 3rd quarter. American Century Companies Inc. now owns 2,655,328 shares of the medical technology company’s stock worth $34,440,000 after purchasing an additional 523,323 shares in the last quarter. Cerity Partners LLC acquired a new stake in shares of Alphatec in the 4th quarter valued at about $28,451,000. Finally, Intrinsic Edge Capital Management LLC increased its position in Alphatec by 72.2% in the 4th quarter. Intrinsic Edge Capital Management LLC now owns 1,599,849 shares of the medical technology company’s stock valued at $24,174,000 after buying an additional 670,788 shares in the last quarter. Institutional investors and hedge funds own 66.35% of the company’s stock.

Insider Buying and Selling

In other news, CFO John Todd Koning sold 37,500 shares of the firm’s stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $12.82, for a total transaction of $480,750.00. Following the completion of the sale, the chief financial officer now owns 393,356 shares in the company, valued at approximately $5,042,823.92. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO John Todd Koning sold 37,500 shares of the company’s stock in a transaction on Wednesday, April 24th. The stock was sold at an average price of $12.82, for a total transaction of $480,750.00. Following the transaction, the chief financial officer now owns 393,356 shares of the company’s stock, valued at approximately $5,042,823.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 50,232 shares of Alphatec stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $10.88, for a total value of $546,524.16. Following the completion of the sale, the general counsel now directly owns 245,638 shares of the company’s stock, valued at approximately $2,672,541.44. The disclosure for this sale can be found here. 22.80% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have issued reports on ATEC shares. Piper Sandler cut their price target on Alphatec from $19.00 to $17.00 and set an “overweight” rating on the stock in a report on Wednesday, May 8th. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 price target on shares of Alphatec in a report on Wednesday, May 8th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $25.00 price target on shares of Alphatec in a report on Wednesday, March 20th. One research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Alphatec has an average rating of “Moderate Buy” and an average target price of $21.75.

Alphatec Stock Up 0.8 %

Shares of Alphatec stock opened at $9.98 on Friday. Alphatec Holdings, Inc. has a 52 week low of $8.66 and a 52 week high of $19.14. The business has a 50 day moving average price of $10.84 and a 200-day moving average price of $13.24. The company has a debt-to-equity ratio of 13.63, a current ratio of 2.39 and a quick ratio of 1.49.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings data on Tuesday, May 7th. The medical technology company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The company had revenue of $138.48 million during the quarter, compared to analysts’ expectations of $134.07 million. Alphatec had a negative return on equity of 1,767.81% and a negative net margin of 37.45%. The business’s revenue for the quarter was up 26.9% compared to the same quarter last year. During the same period last year, the company earned ($0.40) earnings per share. Equities research analysts predict that Alphatec Holdings, Inc. will post -1.04 earnings per share for the current year.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.